科興製藥(688136.SH)觸及漲停 提示:與科興中維沒關係!
格隆匯6月2日丨科興製藥(688136.SH)今日跳空上漲,盤中觸及漲停板,報價47.51元,股價創年內新高,市值逼近百億。有媒體稱“旗下產品或被WHO列入緊急使用清單 科興製藥盤中漲停”,實際上,科興製藥與生產新冠疫苗的“北京科興中維”並沒有關係,與科興中維有直接關係的上市公司只有2家,分別是港股中國生物製藥和美股科興生物。科興製藥主要從事重組蛋白藥物和微生態製劑的研發、生產、銷售,主要產品包括重組蛋白藥物“人促紅素”、“人干擾素α1b”、“人粒細胞刺激因子”,微生態製劑藥物“酪酸梭菌二聯活菌”。去年一季度國內新冠疫情全面爆發,科興製藥生產的干擾素-α作為《新型冠狀病毒肺炎診療方案》推薦的抗病毒治療藥物需求量大幅增加,當季營收創歷史新高。隨着國內疫情好轉,抗病毒藥物市場需求量隨之下降,公司人干擾素α1b產品銷售恢復以往正常水平。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.